TCR2 Therapeutics (TCRR) PT Raised to $45 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Six dead in 'stampede-like' incident at India temple, ANI says
TCR2 Therapeutics (TCRR) Prices 8M Share Common Offering at $15.50/Sh
July 29, 2020 5:47 AM EDTTCR2 Therapeutics Inc. (NASDAQ: TCRR) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share. TCR2 also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $124.0 million, excluding any exercise of the underwriters option to... More
TCR2 Therapeutics (TCRR) PT Raised to $32 at Wedbush
July 27, 2020 6:20 AM EDTWedbush analyst David Nierengarten raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $32.00 (from $25.00) while maintaining a Outperform rating.... More
TCR2 Therapeutics (TCRR) to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
July 24, 2020 4:06 PM EDTTCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for... More
